연구동향 분석
박사

Elevated BLT2 expression levels in cancer cells are implicated in chemoresistance, proliferation and migration : Implication of Elevated BLT2 expression in mediating the chemoresistance and the proliferation of cancer cells

( Jaein Park ) 2019년

논문상세정보
인용/피인용
' Elevated BLT2 expression levels in cancer cells are implicated in chemoresistance, proliferation and migration : Implication of Elevated BLT2 expression in mediating the chemoresistance and the proliferation of cancer cells' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • BLT2
  • cancer
  • colon
  • micro-environment
  • ovary
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
439 0

0.0%

' Elevated BLT2 expression levels in cancer cells are implicated in chemoresistance, proliferation and migration : Implication of Elevated BLT2 expression in mediating the chemoresistance and the proliferation of cancer cells' 의 참고문헌

  • Z. Han, J. Feng, Z. Hong, L. Chen, W. Li, S. Liao, X.Wang, T. Ji, S.Wang, D. Ma, G. Chen, Q. Gao, Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells, Biochem. Biophys. Res. Commun. 435 (2013) 188–194.
  • Z. Duan, R. Foster, D.A. Bell, J. Mahoney, K. Wolak, A. Vaidya, C. Hampel, H. Lee, M.V. Seiden, Signal transducers and activators of transcription 3 pathway activation in drugresistant ovarian cancer, Clin. Cancer Res. 12 (2006) 5055– 5063.
  • Y.R. Kim, M.K. Park, G.J. Kang, H.J. Kim, E.J. Kim, H.J. Byun, M.Y. Lee, C.H. Lee, Leukotriene B4 induces EMT and vimentin expression in PANC-1 pancreatic cancer cells: involvement of BLT2 via ERK2 activation, Prostaglandins Leukot. Essent. Fat. Acids 115 (2016) 67–76.
  • Y. Wang, X.L. Niu, Y. Qu, J. Wu, Y.Q. Zhu, W.J. Sun, L.Z. Li, Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells, Cancer Lett. 295 (2010) 110–123.
  • Y. Sun, Y. Zhao, X. Wang, L. Zhao, W. Li, Y. Ding, L. Kong, Q. Guo, N. Lu, Wogonoside prevents colitis-associated colorectal carcinogenesis and colon cancer progression in inflammation-related microenvironment via inhibiting NFkappaB activation through PI3K/Akt pathway, Oncotarget, 7 (2016) 34300-34315.
  • X. Zhong, H.N. Lee, Y.J. Surh, RvD1 inhibits TNFalphainduced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells, Biochem Biophys Res Commun, 496 (2018) 316-323.
  • X. Zhang, P. Liu, B. Zhang, A. Wang, M. Yang, Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells, Cancer Genet. Cytogenet. 197 (2010) 46–53.
  • X. Xie, H. Xiao, F. Ding, H. Zhong, J. Zhu, N. Ma, J. Mei, Over-expression of prolyl hydroxylase‑1 blocks NF-kappaBmediated cyclin D1 expression and proliferation in lung carcinoma cells, Cancer Genet. 207 (2014) 188–194.
  • X. Hua, A.I. Phipps, A.N. Burnett-Hartman, S.V. Adams, S. Hardikar, S.A. Cohen, J.M. Kocarnik, D.J. Ahnen, N.M. Lindor, J.A. Baron, P.A. Newcomb, Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival, J. Clin. Oncol. 35 (2017) 2806–2813.
  • X. Chen, Z.F. Lin, W.J. Xi, W. Wang, D. Zhang, F. Yang, Y.F. Li, Y. Huo, T.Z. Zhang, Y.H. Jiang, W.W. Qin, A.G. Yang, T. Wang, DNA methylation-regulated and tumor-suppressive roles of miR-487b in colorectal cancer via targeting MYC, SUZ12, and KRAS, Cancer Med, 8 (2019) 1694-1709.
  • W. Li, W. Zhu, C. Lv, H. Qu, K. Xu, H. Li, Y. Du, G. Liu, Y. Wang, H.J. Wei, H.Y. Zhao, Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells, Oncol Lett, 15 (2018) 1881-1887.
  • W. Hu, T. Shen, M.H. Wang, Cell cycle arrest and apoptosis induced by methyl 3,5‑dicaffeoyl quinate in human colon cancer cells: involvement of the PI3K/Akt and MAP kinase pathways, Chem. Biol. Interact. 194 (2011) 48–57.
  • V. Syed, G. Ulinski, S.C. Mok, S.M. Ho, Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells, J. Natl. Cancer Inst. 94 (2002) 617–629.
  • T. Yokomizo, Y. Ogawa, N. Uozumi, K. Kume, T. Izumi, T. Shimizu, cDNA cloning and mutagenesis study of leukotriene B4 12‑hydroxydehydrogenase, Adv. Exp. Med. Biol. 407 (1997) 151–156.
  • T. Yokomizo, K. Kato, K. Terawaki, T. Izumi, T. Shimizu, A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders, J. Exp. Med. 192 (2000) 421–432.
  • T. Arumugam, V. Ramachandran, K.F. Fournier, H.Wang, L. Marquis, J.L. Abbruzzese, G.E. Gallick, C.D. Logsdon, D.J. McConkey, W. Choi, Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer, Cancer Res. 69 (2009) 5820–5828.
  • S.V. Nuti, G. Mor, P. Li, G. Yin, TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis, Oncotarget 5 (2014) 7260–7271.
  • S.A. Hosseini, H. Zand, M. Cheraghpour, The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells, Medicina (Kaunas), 55 (2019).
  • S. Zhang, J. Li, P. Xie, T. Zang, H. Shen, G. Cao, Y. Zhu, Z. Yue, Z. Li, STAT3/c-Myc Axis-Mediated Metabolism Alternations of Inflammation-Related Glycolysis Involve with Colorectal Carcinogenesis, Rejuvenation Res, 22 (2019) 138- 145.
  • S. Ogino, G.J. Kirkner, K. Nosho, N. Irahara, S. Kure, K. Shima, A. Hazra, A.T. Chan, R. Dehari, E.L. Giovannucci, C.S. Fuchs, Cyclooxygenase‑2 expression is an independent predictor of poor prognosis in colon cancer, Clin. Cancer Res. 14 (2008) 8221–8227.
  • S. Hong, S. Kim, H.Y. Kim, M. Kang, H.H. Jang, W.S. Lee, Targeting the PI3K signaling pathway in KRAS mutant colon cancer, Cancer Med. 5 (2016) 248–255.
  • S. Danese, A. Mantovani, Inflammatory bowel disease and intestinal cancer: a paradigm of the yin-Yang interplay between inflammation and cancer, Oncogene 29 (2010) 3313– 3323.
  • R.P. Rocconi, T.O. Kirby, R.S. Seitz, R. Beck, J.M. Straughn Jr., R.D. Alvarez, W.K. Huh, Lipoxygenase pathway receptor expression in ovarian cancer, Reprod. Sci. 15 (2008) 321–326.
  • R.M. Goldberg, M.L. Rothenberg, E. Van Cutsem, A.B. Benson 3rd, C.D. Blanke, R.B. Diasio, A. Grothey, H.J. Lenz, N.J. Meropol, R.K. Ramanathan, C.H. Becerra, R. Wickham, D. Armstrong, C. Viele, The continuum of care: a paradigm for the management of metastatic colorectal cancer, Oncologist 12 (2007) 38–50.
  • R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2015, CA Cancer J. Clin. 65 (2015) 5–29.
  • R.C. Sears, J.R. Nevins, Signaling networks that link cell proliferation and cell fate, J Biol Chem, 277 (2002) 11617- 11620.
  • R. Hennig, T. Osman, I. Esposito, N. Giese, S.M. Rao, X.Z. Ding, W.G. Tong, M.W. Buchler, T. Yokomizo, H. Friess, T.E. Adrian, BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation, Br. J. Cancer 99 (2008) 1064–1073.
  • R. Fritsche-Guenther, F. Witzel, S. Kempa, T. Brummer, C. Sers, N. Bluthgen, Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis, Oncotarget 7 (2016) 7960–7969.
  • Q.K. Xie, P. Chen, W.M. Hu, P. Sun, W.Z. He, C. Jiang, P.F. Kong, S.S. Liu, H.T. Chen, Y.Z. Yang, D. Wang, L. Yang, L.P. Xia, The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor, J Transl Med, 16 (2018) 273.
  • P.K. Kreeger, R. Mandhana, S.K. Alford, K.M. Haigis, D.A. Lauffenburger, RAS mutations affect tumor necrosis factorinduced apoptosis in colon carcinoma cells via ERKmodulatory negative and positive feedback circuits along with non-ERK pathway effects, Cancer Res. 69 (2009) 8191–8199.
  • P. Guillem-Llobat, M. Dovizio, A. Bruno, E. Ricciotti, V. Cufino, A. Sacco, R. Grande, S. Alberti, V. Arena, M. Cirillo, C. Patrono, G.A. FitzGerald, D. Steinhilber, A. Sgambato, P. Patrignani, Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells, Oncotarget 7 (2016) 32462–32477.
  • P. Castagnola, W. Giaretti, Mutant KRAS, chromosomal instability and prognosis in colorectal cancer, Biochim. Biophys. Acta 1756 (2005) 115–125.
  • P. Ataie-Kachoie, D.L. Morris, M.H. Pourgholami, Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies, PLoS One 8 (2013), e60817.
  • N.K. Kurrey, S.P. Jalgaonkar, A.V. Joglekar, A.D. Ghanate, P.D. Chaskar, R.Y. Doiphode, S.A. Bapat, Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells, Stem Cells 27 (2009) 2059–2068.
  • N.K. Cho, Y.C. Joo, J.D. Wei, J.I. Park, J.H. Kim, BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development, Am J Cancer Res, 3 (2013) 347-355.
  • N. Guriec, C. Le Jossic-Corcos, B. Simon, J.C. Ianotto, A. Tempescul, Y. Dreano, J.P. Salaun, C. Berthou, L. Corcos, The arachidonic acid- LTB4-BLT2 pathway enhances human B-CLL aggressiveness, Biochim. Biophys. Acta 1842 (2014) 2096–2105.
  • M.Muccioli, F. Benencia, Toll-like receptors in ovarian cancer as targets for immunotherapies, Front. Immunol. 5 (2014) 341.
  • M.K. Park, Y. Park, J. Shim, H.J. Lee, S. Kim, C.H. Lee, Novel involvement of leukotriene B(4) receptor 2 through ERK activation by PP2A down-regulation in leukotriene B(4)- induced keratin phosphorylation and reorganization of pancreatic cancer cells, Biochim. Biophys. Acta 1823 (2012) 2120–2129.
  • M.H. Yoo, H. Song, C.H. Woo, H. Kim, J.H. Kim, Role of the BLT2, a leukotriene B4 receptor, in ras transformation, Oncogene 23 (2004) 9259–9268.
  • M. Zeineldin, M.A. Miller, R. Sullivan, K.L. Neufeld, Nuclear adenomatous polyposis coli suppresses colitis-associated tumorigenesis in mice, Carcinogenesis 35 (2014) 1881–1890.
  • M. Jinushi, Y. Komohara, Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside, Biochim. Biophys. Acta 1855 (2015) 123– 130.
  • M. Ichiba, K. Nakajima, Y. Yamanaka, N. Kiuchi, T. Hirano, Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein, J. Biol. Chem. 273 (1998) 6132–6138.
  • L.M. Shafer, L.W. Slice, Anisomycin induces COX-2 mRNA expression through p38(MAPK) and CREB independent of small GTPases in intestinal epithelial cells, Biochim. Biophys. Acta 1745 (2005) 393–400.
  • L.M. Hess, M. Benham-Hutchins, T.J. Herzog, C.H. Hsu, D.C. Malone, G.H. Skrepnek, M.K. Slack, D.S. Alberts, A metaanalysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer, Int. J. Gynecol. Cancer 17 (2007) 561–570.
  • L. Soucek, J.R. Whitfield, N.M. Sodir, D. Masso-Valles, E. Serrano, A.N. Karnezis, L.B. Swigart, G.I. Evan, Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice, Genes Dev, 27 (2013) 504-513.
  • L. Soucek, J. Whitfield, C.P. Martins, A.J. Finch, D.J. Murphy, N.M. Sodir, A.N. Karnezis, L.B. Swigart, S. Nasi, G.I. Evan, Modelling Myc inhibition as a cancer therapy, Nature, 455 (2008) 679-683.
  • L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, R. De Maria, Identification and expansion of human colon-cancer-initiating cells, Nature, 445 (2007) 111-115.
  • K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126 (2006) 663-676.
  • K. Magudia, A. Lahoz, A. Hall, K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through upregulation of c-myc, J Cell Biol, 198 (2012) 185-194.
  • K. Ieta, F. Tanaka, N. Haraguchi, Y. Kita, H. Sakashita, K. Mimori, T. Matsumoto, H. Inoue, H. Kuwano, M. Mori, Biological and genetic characteristics of tumor-initiating cells in colon cancer, Ann Surg Oncol, 15 (2008) 638-648.
  • K. Field, L. Lipton, Metastatic colorectal cancer-past, progress and future, World J. Gastroenterol. 13 (2007) 3806–3815.
  • K. Bishayee, A.R. Khuda-Bukhsh, 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy, Acta Biochim. Biophys. Sin. 45 (2013) 709– 719 (Shanghai).
  • K. Abubaker, R.B. Luwor, R. Escalona, O. McNally, M.A. Quinn, E.W. Thompson, J.K. Findlay, N. Ahmed, Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden, Front. Oncol. 4 (2014) 75.
  • K. Abubaker, R.B. Luwor, H. Zhu, O. McNally, M.A. Quinn, C.J. Burns, E.W. Thompson, J.K. Findlay, N. Ahmed, Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden, BMC Cancer 14 (2014) 317.
  • J.Y. Kim, W.K. Lee, Y.G. Yu, J.H. Kim, Blockade of LTB4- induced chemotaxis by bioactive molecules interfering with the BLT2-Galphai interaction, Biochem. Pharmacol. 79 (2010) 1506–1515.
  • J.W. Lee, J.H. Kim, Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells, J. Biol. Chem. 288 (2013) 30054–30063.
  • J.M. Seo, S. Park, J.H. Kim, Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2, J. Biol. Chem. 287 (2012) 13840–13849.
  • J.M. Seo, K.J. Cho, E.Y. Kim, M.H. Choi, B.C. Chung, J.H. Kim, Up-regulation of BLT2 is critical for the survival of bladder cancer cells, Exp. Mol. Med. 43 (2011) 129–137.
  • J.A. Choi, J.W. Lee, H. Kim, E.Y. Kim, J.M. Seo, J. Ko, J.H. Kim, Pro-survival of estrogen receptor-negative breast cancer cells is regulated by a BLT2-reactive oxygen species linked signaling pathway, Carcinogenesis 31 (2010) 543–551.
  • J.A. Choi, E.Y. Kim, H. Song, C. Kim, J.H. Kim, Reactive oxygen species are generated through a BLT2-linked cascade in Ras-transformed cells, Free Radic. Biol. Med. 44 (2008) 624–634.
  • J. Yang, X. Guo, T. Wu, K. Niu, X. Ma, Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy, Medicine (Baltimore), 98 (2019) e14420.
  • J. Park, S.Y. Park, J.H. Kim, Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade, Biochim. Biophys. Acta 1863 (2016) 236–243.
  • J. Park, J.H. Jang, J.H. Kim, Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells, Biochim Biophys Acta Mol Cell Res, 1866 (2019) 329-336.
  • J. Kumar, A.C. Ward, Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications, Biochim. Biophys. Acta 1845 (2014) 117–125.
  • J. Itou, S. Tanaka, F. Sato, R. Akiyama, Y. Kawakami,M. Toi, An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer, Biochim. Biophys. Acta 1853 (2015) 27–40.
  • H. Zhang, W. Li, F. Nan, F. Ren, H. Wang, Y. Xu, F. Zhang, MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line, Biochem Biophys Res Commun, 404 (2011) 273-278.
  • H. Land, L.F. Parada, R.A. Weinberg, Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes, Nature, 304 (1983) 596-602.
  • H. Kim, G.S. Park, J.E. Lee, J.H. Kim, A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF７８ 7/DOX breast cancer cells, Br. J. Cancer 109 (2013) 351–359.
  • H. Kim, G.S. Park, J.E. Lee, J.H. Kim, A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF- 7/DOX breast cancer cells, Br. J. Cancer 109 (2013) 351–359.
  • H. Kawasaki, T. Saotome, T. Usui, T. Ohama, K. Sato, Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor, Oncol. Rep. 37 (2017) 3128– 3136.
  • H. Chen, J. Gao, Z. Du, X. Zhang, F. Yang, W. Gao, Expression of factors and key components associated with the PI3K signaling pathway in colon cancer, Oncol. Lett. 15 (2018) 5465–5472.
  • G.S. Park, J.H. Kim, Myeloid differentiation primary response gene 88-leukotriene B4 receptor 2 cascade mediates lipopolysaccharide-potentiated invasiveness of breast cancer cells, Oncotarget 6 (2015) 5749–5759.
  • G.S. Park, J.H. Kim, LPS up-regulates ICAM-1 expression in breast cancer cells by stimulating aMyD88-BLT2-ERK-linked cascade, which promotes adhesion to monocytes, Mol. Cells 38 (2015) 821–828.
  • F. Porell, Geographic variations in hospital discharge rates and discretionary hospital use, J. Health Serv. Res. Policy 4 (1999) 147–153.
  • E.Y. Kim, J.M. Seo, K.J. Cho, J.H. Kim, Ras-induced invasion and metastasis are regulated by a leukotriene B4 receptor BLT2-linked pathway, Oncogene 29 (2010) 1167–1178.
  • E.Y. Kim, J.M. Seo, C. Kim, J.E. Lee, K.M. Lee, J.H. Kim, BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species linked pathway, Free Radic. Biol. Med. 49 (2010) 1072–1081.
  • E.V. Schmidt, The role of c-myc in cellular growth control, Oncogene, 18 (1999) 2988-2996.
  • D.Wang, R.N. Dubois, Eicosanoids and cancer, Nat. Rev. Cancer 10 (2010) 181–193.
  • D.G. DeNardo, D.J. Brennan, E. Rexhepaj, B. Ruffell, S.L. Shiao, S.F. Madden, W.M. Gallagher, N. Wadhwani, S.D. Keil, S.A. Junaid, H.S. Rugo, E.S. Hwang, K. Jirstrom, B.L. West, L.M. Coussens, Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discov. 1 (2011) 54–67.
  • C.A. O'Brien, A. Pollett, S. Gallinger, J.E. Dick, A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature, 445 (2007) 106-110.
  • C. Riccardi, I. Nicoletti, Analysis of apoptosis by propidium iodide staining and flow cytometry, Nat. Protoc. 1 (2006) 1458–1461.
  • C. Pisano, G.S. Bruni, G. Facchini, C. Marchetti, S. Pignata, Treatment of recurrent epithelial ovarian cancer, Ther. Clin. Risk Manag. 5 (2009) 421–426.
  • C. Chen, J. Chen, K.N. Zhao, Editorial: signalling pathways in anti-cancer drug resistance, Curr. Med. Chem. 21 (2014) 3007–3008.
  • B. Liu, Z. Zhou, W. Zhou, J. Liu, Q. Zhang, J. Xia, N. Chen, M. Li, R. Zhu, Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/S phase cell cycle arrest and apoptosis through caspase/cyclin CDK pathways, Mol. Med. Rep. 10 (2014) 1697–1702.
  • A.M. Haslehurst, M. Koti, M. Dharsee, P. Nuin, K. Evans, J. Geraci, T. Childs, J. Chen, J. Li, J. Weberpals, S. Davey, J. Squire, P.C. Park, H. Feilotter, EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer, BMC Cancer 12 (2012) 91.
  • A.A. Tahir, N.F. Sani, N.A. Murad, S. Makpol, W.Z. Ngah, Y.A. Yusof, Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT29 cells, Nutr. J. 14 (2015) 31.
  • A. Wolfer, B.S. Wittner, D. Irimia, R.J. Flavin, M. Lupien, R.N. Gunawardane, C.A. Meyer, E.S. Lightcap, P. Tamayo, J.P. Mesirov, X.S. Liu, T. Shioda, M. Toner, M. Loda, M. Brown, J.S. Brugge, S. Ramaswamy, MYC regulation of a "poorprognosis" metastatic cancer cell state, Proc Natl Acad Sci U S A, 107 (2010) 3698-3703.
  • A. Valverde, J. Penarando, A. Canas, L.M. Lopez-Sanchez, F. Conde, S. Guil-Luna, V. Hernandez, C. Villar, C. Morales- Estevez, J. de la Haba-Rodriguez, E. Aranda, A. Rodriguez- Ariza, The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RASFOXM1- beta- catenin signaling axis, Oncotarget 8 (2017) 21754–21769.
  • A. Subramaniam, M.K. Shanmugam, E. Perumal, F. Li, A. Nachiyappan, X. Dai, S.N. Swamy, K.S. Ahn, A.P. Kumar, B.K. Tan, K.M. Hui, G. Sethi, Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma, Biochim. Biophys. Acta 1835 (2013) 46–60.
  • A. Musella, C. Marchetti, I. Palaia, G. Perniola, M. Giorgini, F. Lecce, L. Vertechy, R. Iadarola, F. De Felice, M. Monti, L. Muzii, R. Angioli, P.B. Panici, Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: a single-institution experience, Ann. Surg. Oncol. (2015).
  • A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancerrelated inflammation, Nature 454 (2008) 436–444.
  • A. Korniluk, O. Koper, H. Kemona, V. Dymicka-Piekarska, From inflammation to cancer, Ir J Med Sci, 186 (2017) 57-62.
  • A. Isobe, K. Sawada, Y. Kinose, C. Ohyagi-Hara, E. Nakatsuka, H. Makino, T. Ogura, T. Mizuno, N. Suzuki, E. Morii, K. Nakamura, I. Sawada, A. Toda, K. Hashimoto, S. Mabuchi, T. Ohta, K. Morishige, H. Kurachi, T. Kimura, Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer, PLoS One 10 (2015), e0118080.
  • A. Ihara, K. Wada, M. Yoneda, N. Fujisawa, H. Takahashi, A. Nakajima, Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer, J. Pharmacol. Sci. 103 (2007) 24–32.
  • A. Goel, C.R. Boland, Epigenetics of colorectal cancer, Gastroenterology, 143 (2012) 1442-1460 e1441.
  • A. Bardelli, S. Siena, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, J. Clin. Oncol. 28 (2010) 1254–1261.